Fig. 3

Prediction of OS with submitted models. A Bootstrapped estimates of model performance in CheckMate 026 (Boxes are bound by the 25th and 75th percentile). B Classification principle of the I-MIRACLE model. C I-MIRACLE performance in the chemotherapy and nivolumab arms of CheckMate 026. D I-MIRACLE performance in the chemotherapy and nivolumab + ipilimumab arms of CheckMate 227. BL baseline, C-index concordance index, DSS BM difference in squared scaled basal metrics, ICR immunologic constant of rejection, OS overall survival, PD-L1 programmed death ligand 1, PFS progression-free survival, TMB tumor mutational burden